Insider · CIK 0001717441
Ghiath M. Sukhtian
Files at OTLK (Outlook Therapeutics, Inc.). First filing Jun 1, 2026, latest Aug 14, 2026.
In brief
Ghiath M. Sukhtian files SEC Form 4 as director and 10% owner at OTLK (Outlook Therapeutics, Inc.). Since Jun 1, 2026, Ghiath M. Sukhtian has reported 2 open-market buys worth $7.5M and 0 open-market sells worth $0, the latest filed on Aug 14, 2026.
A track record needs three past buys with six months of prices behind them; Ghiath M. Sukhtian has 0, so none is measured yet.
The newest scored trade: bought $2.5M of OTLK on Aug 12, 2026, filed Aug 14, 2026, scored 56 (moderate). In the last 12 months: 2 buys worth $7.5M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OTLK: Outlook Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Outlook Therapeutics, Inc. | $2.5M 2,525,252 shares | +11% | - | |
| 65Notable | Outlook Therapeutics, Inc. | $5.0M 8,539,709 shares | +63% | - |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +2,525,252 | $0.99 | $2.5M | 24,617,320 | Aug 14, 2026 |
| Aug 12, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +2,525,252 | $0.00 | $0 | 2,525,252 | Aug 14, 2026 |
| May 28, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +8,539,709 | $0.59 | $5.0M | 22,092,068 | Jun 1, 2026 |
| May 28, 2026 | OTLK Outlook Therapeutics, Inc. | HExpiration of long derivative Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jun 1, 2026 |
| May 28, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jun 1, 2026 |
| May 28, 2026 | OTLK Outlook Therapeutics, Inc. | HExpiration of long derivative Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jun 1, 2026 |
| May 28, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jun 1, 2026 |
| May 28, 2026 | OTLK Outlook Therapeutics, Inc. | HExpiration of long derivative Warrants (right to buy)derivativeindirect: See footnote | -8,571,428 | - | - | 0 | Jun 1, 2026 |
| May 28, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +8,571,428 | - | - | 8,571,428 | Jun 1, 2026 |
| May 27, 2025 | OTLK Outlook Therapeutics, Inc. | AGrant or award Common Stockindirect: See footnote | +4,285,714 | $1.40 | $6.0M | 13,552,359 | May 28, 2025 |
| May 27, 2025 | OTLK Outlook Therapeutics, Inc. | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +8,571,428 | - | - | 8,571,428 | May 28, 2025 |
| Jan 17, 2025 | OTLK Outlook Therapeutics, Inc. | DDisposition to issuer Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jan 22, 2025 |
| Jan 17, 2025 | OTLK Outlook Therapeutics, Inc. | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jan 22, 2025 |
| Jan 17, 2025 | OTLK Outlook Therapeutics, Inc. | MOption exercise Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jan 22, 2025 |
| Jan 17, 2025 | OTLK Outlook Therapeutics, Inc. | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jan 22, 2025 |
| Jan 17, 2025 | OTLK Outlook Therapeutics, Inc. | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jan 22, 2025 |
Questions about Ghiath M. Sukhtian
Answered from the filings on this page, as of the latest one.
Is Ghiath M. Sukhtian buying or selling?
In the last 12 months Ghiath M. Sukhtian reported 2 open-market buys worth $7.5M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2.5M of OTLK on Aug 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Ghiath M. Sukhtian's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ghiath M. Sukhtian has 0.
Where does Ghiath M. Sukhtian file Form 4?
Ghiath M. Sukhtian has filed Form 4 at OTLK (Outlook Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.